Evidence map›Paper›PMID 41679192›Full record

ArticleEBioMedicine2026

Disulfiram metabolite Cu(DDC)

Katie Brookes, Jessica S Fear, Caitlin E M Thornton, Ling Zha, Jana Kim, Benjamin Small, Sarinya Wongsanit, Hannah R Nieto, Holly Adcock, Adam Jones and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Katie BrookesDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Jessica S FearDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Caitlin E M ThorntonDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Ling ZhaDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Jana KimSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Benjamin SmallResearch Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK.
Sarinya WongsanitDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Hannah R NietoDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Holly AdcockSchool of Chemistry, University of Birmingham, Birmingham, UK.
Adam JonesSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Truc T PhamSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Giovanni BottegoniInstitute of Clinical Sciences, University of Birmingham, Birmingham, UK; Università degli Studi di Urbino Carlo Bo, Urbino, Italy.
Liam R CoxSchool of Chemistry, University of Birmingham, Birmingham, UK.
Vinodh KannappanResearch Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK.
Weiguang WangResearch Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK.
Caroline M GorvinDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Daniel G StoverDivision of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA.
Christine SpitzwegDepartment of Internal Medicine IV, University Hospital of Munich, LMU Munich, Munich, Germany; Division Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA.
Sissy JhiangDivision of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA.
Matthew D RingelDivision of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA.
Moray J CampbellDivision of Cancer Biology, Cedars Sinai Cancer, Los Angeles, USA.
Kavitha SunasseeSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Philip J BlowerSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Kristien BoelaertDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Vicki E SmithDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Martin L ReadDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK. Electronic address: m.l.read.20@bham.ac.uk.
Christopher J McCabeDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK. Electronic address: mccabcjz@bham.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExploitation of the sodium iodide symporter (NIS) has potentially broad clinical application across different tumour ablative settings but often fails in aggressive cancer due to diminished transport activity. We aimed to discover whether enhancing NIS function by modulating proteostasis was targetable in vivo, as well as the clinical relevance to radioiodide (RAI) treatment of patients with cancer.

methodsWe used 3D modelling, iterative design, reformulation, RAI uptake, RNA-Seq, cell surface biotinylation assays and NanoBRET in transformed cell lines and primary thyroid cells from patients to identify new drugs targeted at enhancing NIS function and to uncover their respective mechanisms. Systemic drug responses were monitored via

findingsCopper diethyldithiocarbamate (Cu(DDC)

interpretationOur findings reveal a mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.

fundingThis work was funded by the U.S. Department of Defense (BC201532P1), Medical Research Council (CiC/1001505 and MR/Z504828/1), British Thyroid Foundation (1002175). We further acknowledge support from the Wellcome Trust and EPSRC funded Centre for Medical Engineering at King's College London (203148/Z/16/Z), the Wellcome Multiuser Equipment Radioanalytical Facility (212885/Z/18/Z), and the EPSRC programme for Next Generation Molecular Imaging and Therapy with Radionuclides (EP/S019901/1).

Indexed as

DisulfiramIodine RadioisotopesAnimalsBreast NeoplasmsCell Line, TumorDisease Models, AnimalFemaleHumansMiceSingle Photon Emission Computed Tomography Computed TomographySodium-Iodide SymportersSymportersDisulfiramIodine RadioisotopesSodium-Iodide SymportersSymportersBreast cancerNISProteostasisThyroid cancerTranscriptionVCP

Identifiers

PMID41679192
PMCPMC12917385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.